MRI demonstration of gadolinium deposition in bone after monthly triple-dose gadopentetate dimeglumine and correlation with frequency of hypophosphatemia

We retrospectively analyzed data of the BECOME trial to investigate whether serial administration of triple-dose (3-dose) gadopentetate dimeglumine would result in the development of T1 signal-to-noise (S/N) changes in the cranial diploic space and whether S/N changes correlated with on-study hypophosphatemia.

Source: Clinical Imaging - July 28, 2020 Category: Radiology Authors: Devin Bageac, John J. DeBevits, Reshma Munbodh, Joshua Kaplan, Rong Wu, Paul A. DiCamillo, Chaoran Hu, Yanlin Wang, David Karimeddini, Robert T. Naismith, Suhayl Dhib-Jalbut, Leo Wolansky Tags: Neuroradiology Source Type: research